KEZAR LIFE SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8574 USD | +0.32% |
|
+6.52% | -9.50% |
Presentation Operator MessageOperator (Operator)Welcome to Kezar Life Sciences 2021 Investor a...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.8574
USD
Average target price
11.67
USD
Spread / Average Target
+1,260.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.50% | 62.42M | |
| -1.43% | 104B | |
| +8.96% | 105B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- KZR Stock
- News Kezar Life Sciences, Inc.
- Transcript : Kezar Life Sciences, Inc. - Analyst/Investor Day
